{"schema_version":"secwatch.filing_event.v1","accession":"0001835268-26-000012","form_type":"8-K","ticker":"CNTB","cik":"0001835268","company_name":"Connect Biopharma Holdings Ltd","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.451164+00:00","generated_at":"2026-05-15T08:13:30.403849+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Connect Biopharma FY2025 net loss $55.5M; cash runway extended by $20.2M placement","bullets":["Net loss FY2025 $55.5M ($1.00 per share) vs $15.6M ($0.28 per share) in FY2024.","Cash and equivalents $44.3M at Dec 31, 2025; with private placement net proceeds, runway into H2 2027.","Private placement raised $20.2M gross from 6.13M shares at $3.25 each; closed March 31, 2026.","Phase 1 IV rademikibart showed rapid FEV1 improvement in asthma/COPD; Phase 2 Seabreeze STAT topline data expected mid-2026.","R&D expense increased to $37.8M (FY2025) from $29.3M due to Phase 2 study initiation."],"urls":{"canonical":"https://secwatch.observer/filing/0001835268-26-000012","json":"https://secwatch.observer/filing/0001835268-26-000012.json","markdown":"https://secwatch.observer/filing/0001835268-26-000012.md","text":"https://secwatch.observer/filing/0001835268-26-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000012/0001835268-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000012/cntb-20260331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:13:30.403849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d4c3c398914f3b1c00daf31ee1b277170be8def2","claim":"Connect Biopharma Holdings Ltd reported financial results for the three and twelve months ended December 31, 2025.","evidence_excerpt":"On March 31, 2026, Connect Biopharma Holdings Limited (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000012/0001835268-26-000012-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and twelve months ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}